MaSS-CKD v1.0
Research type
Research Study
Full title
Multimorbidity and Sarcopenia Feasibility Study in Chronic Kidney Disease
IRAS ID
328554
Contact name
Mohamed Tarek Eldehni
Contact email
Sponsor organisation
University Hospitals of Derby and Burton NHS Foundation Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
The aim of this research study is to look at the body composition (such as muscle and fat) in people with chronic kidney disease (CKD) and comparing it with body composition is people without CKD. We currently understand loss of muscle function and mass (sarcopenia) affect the general health of people as they age, but this process seems to be more common, and occurs earlier in people with CKD. There is limited evidence in this area, and we believe that if we understand when and how sarcopenia affects people with CKD, we can guide future trials and treatments to help treat sarcopenia, and in turn improve quality of life and health outcomes in people with CKD.
In this study, we hope to follow up people with CKD in two visits a year apart. In both visits, we will measure the participants body composition and estimated kidney function using 2 different testing methods - Cystatin C eGFR and Creatinine eGFR. Using both the results in a formula, the creatinine muscle index can be calculated. If this index correlated with sarcopenia, it will be helpful tool in the care of people with CKD as will be a easy to use screening tool for sarcopenia in this population.REC name
London - Bromley Research Ethics Committee
REC reference
23/PR/1352
Date of REC Opinion
1 Dec 2023
REC opinion
Further Information Favourable Opinion